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ABSTRACT
Objective: To evaluate insulin resistance and lipid profile in women with congenital adrenal 
hyperplasia (CAH) caused by classical 21-hydroxylase deficiency (21OHD), and their association 
with body mass index (BMI) and corticosteroid dosage. Subjects and methods:  We assessed 
BMI, waist circumference, current glucocorticoid dosage, glucose, insulin and lipid profile in 
eighteen young women (mean ± SD, 19.3 ± 3.0 years) with 21OHD CAH. Results: BMI was nor-
mal in 12 patients, 5 of them were overweight, and 1 was obese. Waist circumference was high 
in 7 patients. Fasting insulin and HOMA-IR were elevated in seven and eight patients, respec-
tively. Total cholesterol and triglycerides were high in only two patients, and HDL-cholesterol 
was low in four. Insulin resistance was not associated with BMI, waist circumference or gluco-
corticoid dose. Conclusions: Young women with 21OHD CAH had infrequent dyslipidemia, but 
had a higher prevalence of insulin resistance and central obesity, that were independent of BMI 
or corticosteroid dosage. Arq Bras Endocrinol Metab. 2011;55(8):646-52
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RESUMO
Objetivo: Avaliar a presença de resistência insulínica e dislipidemia em mulheres com hiperpla-
sia adrenal congênita (HAC) por deficiência da 21-hidroxilase (21OHD) e investigar a associação 
com índice de massa corporal (IMC) e dose de glicocorticoide prescrita. Pacientes e métodos: 
Em 18 mulheres jovens (média ± DP, 19,3 ± 3,0 anos), avaliamos IMC, circunferência abdominal, 
dose de glicocorticoide, glicemia, insulinemia e perfil lipídico. Resultados: O IMC foi normal 
em 12 pacientes; 5 apresentavam sobrepeso e 1 apresentou obesidade. Circunferência abdo-
minal estava aumentada em 7 pacientes. Insulinemia de jejum e HOMA-IR estavam elevados 
em 7 e 8 pacientes, respectivamente. Apenas 2 pacientes apresentaram aumento de colesterol 
total ou de triglicérides e 4, diminuição dos níveis de HDL-colesterol. Resistência insulínica não 
apresentou associação com IMC, circunferência abdominal ou dose de glicocorticoide prescrita. 
Conclusão: Mulheres jovens com CAH 21OHD apresentaram pouca dislipidemia, mas tiveram 
alta prevalência de resistência insulínica e obesidade central, independentemente do IMC e da 
dose de glicocorticoide prescrita. Arq Bras Endocrinol Metab. 2011;55(8):646-52
Descritores
Hiperplasia adrenal congênita; resistência insulínica; dislipidemia; obesidade
INTRODUCTION
ongenital adrenal hyperplasia (CAH), in the ma-
jority of the cases, is caused by 21-hydroxylase 
deficiency (21OHD) (1). The classic form of 21OHD 
is divided into two variants: the simple virilizing form 
(SV; characterized by deficient cortisol production and 
increased androgen production), and the salt-wasting 
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form (SW). In addition to the same symptoms ob-
served in SV, a deficiency in aldosterone production 
may occur (2). The treatment of the classic form of 
21OHD is designed to effectively replace cortisol and 
aldosterone, and to control symptoms of excess andro-
gen by using the lowest possible dose of glucocorti-
coid. However, if this replacement does not correctly 
meet individual physiological requirements, patients 
can develop either hyperandrogenism or hypercor-
tisolism. The former can lead to early puberty, short 
stature, high lean mass and infertility, while the latter 
may lead to short stature, insulin resistance, osteopo-
rosis, high fat mass and obesity (2-3).
There are few studies of the effects of adrenal hypo-
function and early exposure to hyperandrogenism on 
insulin secretion and obesity (1). These effects are too 
uncertain to allow the general practitioner, who treats 
patients with CAH, to make decisions based on the-
rapeutic principles. Studies in animal models suggest 
that prenatal and neonatal androgen exposure increa-
se adiposity and insulin resistance, and alters lipolysis 
in adulthood, indicating that androgens may induce 
metabolic reprogramming (4-7). Transient androgen 
exposure, early in the reproductive life of rats, may 
have a prolonged adverse effect on insulin sensitivity 
(6-7). Interventions that avoid androgen exposure in 
early in life could prevent long term metabolic conse-
quences (4).
Adult patients with classical CAH have a higher fre-
quency of obesity, visceral adiposity, hyperinsulinism, 
insulin resistance and hyperandrogenism, compared 
with normal individuals (1,8-20). However, it is not 
clear whether hyperinsulism is due to increased obesi-
ty in these patients, or if it is inherent to the disorder 
itself. Adrenomedullary dysfunction and intermittent 
hypercortisolism are linked to these abnormalities, whi-
ch predispose these patients to a higher risk of metabo-
lic syndrome and atherosclerosis (1,8-20). 
The growing need to prevent chronic cardiovascular 
diseases during childhood increases the importance of 
understanding lipid metabolism and insulin resistance 
of CAH patients, since cardiovascular diseases are pre-
sently the main cause of morbidity and mortality in de-
veloped countries (21,22).
The aims of this study were to evaluate insulin re-
sistance and lipid profile in young women with classical 
21OHD CAH, and to analyze the associations between 
insulin resistance, body mass index (BMI), dyslipidemia 
and glucocorticoid doses.
SUBJECTS AND METHODS
We evaluated young adult women, between 14 and 23 
years old, with classical 21OHD CAH,  breasts Tanner 
stage 4 or 5, and who had reached their final height 
(defined as growth velocity lower than 1 cm in the pre-
vious year). Only patients with complete anthropome-
tric and laboratory evaluations were included in this 
study. This was a cross sectional study, and it was appro-
ved by the local Ethics Committee board beforehand. 
Since initial care in the Pediatric Endocrinology 
outpatient clinic of the Clinical Hospital at Unicamp, 
the same doctor treated all the patients using a dietetic 
and behavioral therapeutic approach. None of the 
patients used hypoglycemic or hypolipidemic drugs. 
Diagnosis of 21OHD CAH was determined during 
the first year of life by clinical features and hormonal 
measurements, and it was confirmed later on by 
molecular genetic testing (23,24). 
Patients were evaluated for weight, height, arterial 
blood pressure, waist circumference, Tanner pubertal 
stage, and their current type of glucocorticoid repla-
cement. We used the BMI criteria of the World Health 
Organization (WHO), which considers normal weight 
from 18.5 to 24.9 kg/m2, overweight from 25 to 29.9 
kg/m2, and obesity ≥ 30 kg/m (25). Waist circumfe-
rence ≥ 80 cm was considered increased, according to 
the International Diabetes Federation (IDF) (26). Ab-
normal blood pressure was defined as ≥ 130 mmHg for 
systolic pressure, and  ≥ 85 mmHg for diastolic pres-
sure, according to the IDF, the American Heart Asso-
ciation (AHA), and the Brazilian Society of Cardiology 
(SBC) (26-28).
After a 12-hour fast, a serum sample was collec-
ted and glucose, insulin, total cholesterol, choleste-
rol fractions, and triglycerides were measured. Serum 
insulin was analyzed by chemiluminescence (Siemens 
Healthcare Diagnostics Products kit and Immulite 
Analyzer(R)). The inter-assay coefficient of variation was 
6.4%, with 8.5% detectable cross-reaction with proinsu-
lin, and with no cross-reaction with C-peptide or glu-
cagon. Normal insulin range was defined as 6.0 to 28.4 
μU/mL.
The other variables were measured by colorime-
tric assays. Total cholesterol levels above 200 mg/dL, 
LDL-cholesterol higher than 160 mg/dL and triglyce-
rides over 150 mg/dL were defined as high, according 
to the SBC (28). For HDL-cholesterol, values below 
50 mg/dL were considered low (27). 
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To evaluate insulin resistance (IR) we used both 
fasting insulin and the homeostasis model assessment 
(HOMA-IR) (29). We considered insulin resistance as 
fasting insulin ≥ 15 µU/mL, for the established assay 
(30). We used the HOMA-IR cutoff point for Brazilian 
populations, which considers insulin resistance results 
over 2.71 (31-33).
To calculate current glucocorticoid doses, we trans-
formed prednisone, prednisolone and dexamethasone 
into hydrocortisone equivalents, by multiplying the 
prednisone or prednisolone dose by 4 and dexame-
thasone by 24 (34). These hydrocortisone equivalents 
were divided by body surface area (m2BS) for compari-
son. We defined two dose groups, ≤ 20 mg/m2BS/day, 
and above this level, since many studies use this cutoff 
point to define high treatment doses (1-3). 
Metabolic syndrome was identified if the patient 
presented central obesity plus two or more of the 
following conditions: high triglycerides, low HDL-
-cholesterol level, systemic hypertension (or use of any 
antihypertensive drug), and high fasting glucose level 
(or previously diagnosed type 2 diabetes mellitus) (26).
Data were recorded and analyzed by SPSS(R) version 
16.0 for Windows(R) (SPSS Inc., Chicago, IL, USA). 
For continuous variables, means, medians, standard 
deviations (SD), minimum and maximum values were 
determined. To evaluate the association between the 
variables, we defined binomial categories and used the 
Fisher’s two-sided exact test. The correlation between 
continuous variables was analyzed by Spearman’s rank 
correlation coefficient. We used p < 0.05 as the signifi-
cance level for all analyses.
RESUlTS
Eighteen patients, from 14.5 to 23.3 years old, fulfilled 
the inclusion criteria. The mean time of follow-up was 
18.2 ± 3.0 years (range, 13.2-22.4 years). Ten patients 
had the salt-wasting form of CAH, and 8 had the non-
-salt-wasting form or simple virilizing form (Table 1). 
Mean final height was 156.0 cm.
BMI was normal in 12 patients, 5 women were 
overweight and only one was obese. Waist circumferen-
ce was increased in 7 patients. Systolic blood pressure 
ranged from 80.0 to 130.0 (mean ± SD, 105.0 ± 12.9), 
and was high in one patient; diastolic pressure ranged 
from 50.0 to 90.0 (mean ± SD, 69.4 ± 10.6), and 
was high in another patient. Waist circumference was 
significantly associated with BMI (Fisher’s exact test, 
p = 0.013); 5 out of the 6 patients with excess weight 
had increased waist circumference, while only 2 out 
of 12 patients with normal weight had increased waist 
circumference.
Total cholesterol was high in 2 patients, HDL-cho-
lesterol low in 4 and LDL-cholesterol was uniformly 
normal. Triglycerides were high in 2 patients. Fasting 
glucose was normal in all patient; 7 patients had high 
levels of fasting insulin, and 8 had high HOMA-IR.
Only 2 of the 7 patients with increased waist cir-
cumference had high fasting insulin levels, and 3 had 
high HOMA-IR. Of the 11 patients with normal waist 
circumference, 5 had high fasting insulin levels, and 5 
had high HOMA-IR (Table 2). Therefore, there was 
no association between waist circumference and insulin 
resistance (fasting insulin, p = 0.637; HOMA-IR, p = 
1.0). Concerning insulin resistance, 3 out of 6 patients 
with excess weight had high fasting insulin level, and 
4 had high HOMA-IR; in contrast, among the 12 pa-
tients with normal weight, 4 had high fasting insulin, 
and 4 had high HOMA-IR. However, insulin resistance 
was not associated with excess weight, and it was inde-
pendent of BMI (fasting insulin, p = 0.627; HOMA-
-IR, p = 0.321).
The types of glucocorticoids used on the day of 
blood sample collection were: 5 patients were taking 
hydrocortisone, 8 were taking prednisone or predni-
solone, and 5 were taking dexamethasone. Glucocor-
ticoid doses, converted to hydrocortisone equivalents, 
ranged from 6.67 to 29.25 mg/m2BS/day (mean ±, 
18.3 ± 6.1). Seven patients were taking doses above 20 
mg/m2BS/day, and 11 were taking doses below this 
value. The presence of dyslipidemia in this group was 
independent of the current glucocorticoid dose (total 
cholesterol, p = 0.497; HDL-cholesterol, p = 1.0; tri-
glycerides, p = 1.0). There was no association between 
the current glucocorticoid dose and excess weight, 
increased waist circumference, or high blood pressu-
re (excess weight, p = 1.0; waist circumference, p = 
1.0; systolic blood pressure, p = 0.389; diastolic blood 
pressure, p = 1.0; Table 3). There was no association 
between glucocorticoid dose and insulin resistance, ei-
ther (fasting insulin, p = 1.0; HOMA-IR, p = 0.630, 
Table 3), and no correlation between glucocorticoid 
dose and HOMA-IR (Spearman correlation coefficient 
= 0.145; p = 0.567).
According to the criteria of the International Dia-
betes Federation (IDF), none of the patients had me-
tabolic syndrome.
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Table 1. Data of 18 young women with the classical form of 21-hydroxylase deficiency 
Patient
number
Age
years
BMI
kg/m2
Hydro 
equivalent
mg/m2BS/day
Waist
cm
Glucose
mg/dl
Insulin
μUI/ml HOMA IR
Cholesterol
mg/dl
HDl
mg/dl
lDl
mg/dl
Triglycerides
mg/dl
1* 18.0 29.4 19.9 81.0 79.0 11.3 2.2 205.0 72.0 117.0 82.0
2** 22.5 19.7 17.5 76.0 77.0 8.4 1.6 184.0 75.0 93.0 78.0
3* 22.4 26.9 10.0 90.0 75.0 9.7 1.8 265.0 67.0 152.0 229.0
4** 18.8 25.1 24.7 100.0 78.0 16.3 3.1 154.0 38.0 99.0 86.0
5** 16.9 24.1 18.5 75.0 78.0 4.7 0.9 165.0 59.0 88.0 89.0
6** 22.0 19.7 20.3 68.2 77.0 7.2 1.4 174.0 72.0 92.0 51.0
7* 15.7 19.1 16.2 73.0 71.0 17.6 3.1 153.0 60.0 78.0 73.0
8* 15.6 20.2 24.6 71.0 72.0 8.1 1.4 177.0 81.0 88.0 42.0
9** 17.3 24.7 21.8 81.5 69.0 8.6 1.5 167.0 61.0 96.0 48.0
10** 23.3 15.7 18.5 66.0 79.0 6.0 1.2 156.0 67.0 73.0 81.0
11* 17.5 27.5 23.6 81.0 92.0 14.2 3.2 171.0 35.0 95.0 207.0
12** 21.9 22.5 10.7 71.0 87.0 33.8 7.3 160.0 67.0 81.0 60.0
13** 16.2 23.5 29.2 73.0 80.0 24.1 4.8 126.0 54.0 62.0 50.0
14** 22.2 22.5 17.3 68.0 86.0 5.17 1.1 144.0 32.0 99.0 64.0
15* 14.4 31.1 8.7 92.0 81.0 23.0 4.6 172.0 59.0 109.0 45.0
16* 22.1 24.9 6.7 85.0 79.0 4.6 0.9 155.0 83.0 48.0 118.0
17** 18.5 25.5 18.5 78.0 68.0 19.7 3.3 158.0 47.0 95.0 80.0
18* 22.7 21.0 22.7 70.0 78.0 18.3 3.5 179.0 69.0 100.0 51.0
mean ± SD 19.3 ± 3 23.5 ± 3.9 18.3 ± 6.1 77.8 ± 9.3 77.9 ± 6.4 13.4 ± 8.1 2.6 ± 1.7 170.3 ± 29.2 61 ± 14.9 92.5 ± 22 85.2 ± 52.2
min-max 14.4-23.3 15.7-31.1 6.7-29.2 66.0-100.0 65.0-92.0 4.6-33.8 0.9-7.3 126.0-265.0 32.0-83.0 48.0-152.0 42.0-229.0
*: Non salt-wasting form; **: Salt-wasting form; BMI: body mass index; HOMA-IR: Homeostasis model assessment; hydro equivalent: hydrocortisone equivalent dosage. 
Table 2. Insulin resistance according to excess weight and glucocorticoid 
dosage in 18 young women with 21-hydroxylase deficiency
Fasting insulin 
(≥ 15 μU/ml)
HOMA-IR 
(≥ 2.71)
Normal Resistant Normal Resistant
Normal waist circumference 6 5 6 5
Increased waist circumference 5 2 4 3
Excess weight 3 3 2 4
No excess weight 8 4 8 4
< 20 mg/m2BS/Day 7 4 7 4
> 20 mg/m2BS/Day 4 3 3 4
Total 11 7 10 8
There was no association between waist circumference or excess weight or glucocorticoid dose 
and insulin resistance. Fisher’s exact test: fasting insulin x waist circumference, p = 0.637; fasting 
insulin x excess weight, p = 1.0; fasting insulin x glucocorticoid dose. p = 1.0; HOMA-IR x waist 
circumference, p = 1.0; HOMA-IR x excess weight, p = 0.321; HOMA-IR x glucocorticoid dose p 
= 0.630.
Table 3. Frequency of abnormal clinical and laboratory evaluations 
according to glucocorticoid dose in 18 young women with classical 
21-hydroxylase deficiency
20 mg/
m2BS/day
> 20 mg/
m2BS/day p value*
Excess weight 4 2 p = 1.0
Increased waist circumference 4 3 p = 1.0
High systolic blood pressure 0 1 p = 0.389
High fast insulin 4 3 p = 1.0
High HOMA-IR 4 4 p = 0.63
High total cholesterol 2 0 p = 0.497
Low HDL-cholesterol 2 2 p =1.0
High triglycerides 1 1 p = 1.0
*: Fisher’s exact test.
DISCUSSION
There are few studies of metabolic disorders in young 
women with CAH (1). Our study addressed the ques-
tion of whether risk factors for either cardiovascular di-
sease or type 2 diabetes mellitus are directly associated 
with CAH itself, or related to other diseases frequen-
tly found in these patients, i.e. obesity, dyslipidemia, 
hypertension, and excess glucocorticoid (8-20). 
Unlike the great majority of published studies on 
patients with CAH, we did not find a high propensity 
Metabolic evaluation in CAH
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for obesity or excess weight (8-12,14-15,18-19). We 
believe that this finding was due to the rigorous clinical 
management of our patients since diagnosis; they were 
followed up by the same doctor, and they received gui-
dance that emphasized adequate nutrition and adhe-
rence to medication.
In the majority of studies of adult females with 
CAH, patients were either taking excessive doses of 
glucocorticoid in order to control the inherent hype-
randrogenism (8), or they had not been previously tre-
ated (14,19). In contrast, our study group was treated 
with glucocorticoid replacement since their first mon-
ths of life. Studies on children and adolescents with 
CAH had small number of patients and, different from 
our study, their patients showed a wide age range and 
pubertal status, making comparisons with our group 
difficult (15,18).
Studies with animal models suggest that prenatal 
and neonatal exposure to androgens results in increased 
adiposity, insulin resistance and alterations in lipolysis 
in adulthood, indicating that androgens may induce 
metabolic reprogramming (4-7). 
Studies with sheep showed that fetal hyperandroge-
nism induces polycystic ovaries, and is associated with 
delayed intrauterine growth; rapid postnatal growth 
recovery – both well-known risk factors for insulin re-
sistance – carbohydrate intolerance; and type 2 diabetes 
in adulthood (7). In a hyperandrogenism model using 
female Rhesus monkeys, early prenatal introduction of 
testosterone produced an increase in postnatal adrenal 
androgens, causing hyperandrogenism similar to that 
observed in polycystic ovarian syndrome (PCOS) (5). 
In addition, metabolic changes were observed inclu-
ding aberrant distribution of adipose tissue, defects in 
insulin secretion, and response and accumulation of vis-
ceral fat, independent of obesity (5-7).
Hyperinsulinism and excess androgen may promote 
central body fat distribution, as we observed in our stu-
dy. However, weight and BMI are not sensitive enough 
to detect redistribution of body fat. The prevalence of 
excessive waist circumference (7 of 18 patients), indi-
cated that the changes we found in body composition 
were probably inherent to CAH, suggesting that hype-
randrogenism was responsible for central fat accumula-
tion. Stikkelbroeck and cols. (12) evaluating body com-
position in patients with CAH using Dual-emission 
X-ray absorptiometry, found lean body mass similar to 
controls matched for age, but a significantly increased 
trunk fat mass. However, they found a high incidence 
of excess weight (8 of 12) while, in our study, only 3 
of 18 patients had a BMI above 25 mg/m2. Gonçalves 
and cols. (11) studied 16 patients with 21-hydroxila-
se deficiency using bioelectrical impedance, and also 
detected a higher proportion of fat mass compared to 
their controls matched for age, with no tendency to-
wards greater BMI. Although this study included some 
of patients from our study, the age of the patients was 
extremely variable (8 to 18 years old), and it was not 
possible to exclude gender and puberty variability in 
this population. 
We found a high frequency of insulin resistance. Se-
ven of 18 patients had high fasting insulin levels, and 
8 had high HOMA-IR, independent of BMI and of 
current dose of glucocorticoid. This suggests that in-
sulin resistance was due to the disease itself. This in-
terpretation is reinforced by studies on newly diagno-
sed CAH patients that show insulin resistance prior to 
glucocorticoid treatment (14,19). Moreover, in our 
data, mean HOMA-IR was even greater than that of 
Chinese women studied by Zhang (19) (mean ± SD, 
2.6 ± 1.7 versus 1.81 + 0.99, respectively). In a Turkish 
study of 18 untreated women with the non-classical 
form of CAH, Saygili and cols. (14) also found ele-
vated HOMA-IR (mean ± SD, 3.2 ± 0.8), which was 
greater than that of controls matched by BMI. Arlt and 
cols. (8), in a multicenter study of 199 women with 
CAH, found a high frequency of insulin resistance, in-
creased waist circumference, and a tendency towards 
diabetes type 2 and gestational diabetes. Different from 
our patients, the majority of these women were obese 
(52.2%) and had clinical signs of excess glucocorticoid 
(stretch marks, osteoporosis and suppressed androgen 
levels). In addition, they did not report molecular con-
firmation of CAH, and the patients had been treated in 
17 different study centers. Despite the increased risk of 
diabetes type 2, evident in our data by insulin resistance 
and excessive waist circumference, none of our patients 
had metabolic syndrome, since we found high blood 
pressure or dyslipidemia in few patients (35). This data 
is similar to that of Falhamar and cols.: they did not find 
dyslipidemia in 27 patients between 18 and 30 years of 
age with CAH. 
Sartorato and cols. (16) showed that insulin resis-
tance per se is capable of causing atherosclerotic disease. 
Hence, we can infer that patients with CAH are sus-
ceptible to cardiovascular disease, as well as at increased 
risk for type 2 diabetes mellitus. Our findings suggest 
that rigorous treatment, with both medication and die-
Metabolic evaluation in CAH
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tary-behavioral guidance, when provided from the first 
year of life, reduces the risk of some of the components 
of the metabolic syndrome.
In conclusion, this group of patients with classical 
21OHD had infrequent dyslipidemia, but had a higher 
incidence of insulin resistance and central obesity that 
were independent of BMI and glucocorticoid doses. 
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